Company news

Entropy Neurodynamics Limited news in 2026

Entropy Neurodynamics Limited's news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities Report and Appendix 4C

October 27, 2026

Quarterly Activities Report and Appendix 4C

October 27, 2026

Entropy presents promising TRP-8803 clinical data at ECNP

October 18, 2026

Change of Director's Interest Notice - HJ

October 13, 2026

Cleansing Notice

October 13, 2026

Application for quotation of securities - ENP

October 13, 2026

TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study

October 6, 2026

2026 AGM Notice of Meeting, Letter of Access and Proxy

October 4, 2026

Notification regarding unquoted securities - ENP

October 2, 2026

Notification of Date of 2026 AGM

September 14, 2026

All Patients Improve, 50% Achieve 12-Week BED Remission

September 13, 2026

Appendix 4E and 2026 Annual Report

August 27, 2026

Investor Webinar Presentation

August 27, 2026

Appendix 4G and Corporate Governance Statement

August 27, 2026

Entropy Advances TRP-8803 to US Phase 2 in Depression

August 25, 2026

Application for quotation of securities - ENP

August 24, 2026

Trading Halt

August 23, 2026

TRP 8803 manufacturing secured for Phase 2/3 advancement

August 18, 2026

Change of Director's Interest Notice - HJ

August 6, 2026

Cleansing Notice

August 6, 2026

Application for quotation of securities - ENP

August 6, 2026

BioShares 2026 Investor Presentation Deck

August 6, 2026

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

August 4, 2026

72-Patient Trial Fast-Tracks TRP-8803 Commercialisation

August 3, 2026

Trading Halt

July 30, 2026

South Africa Grants ENP Broad Fibromyalgia Patent to 2043

July 19, 2026

100% Clinical improvement, 50% Remission in BED study

July 6, 2026

DSMB Clears TRP 8803 to Advance to Cohort 2

June 14, 2026

Entropy completes Cohort 1 dosing in BED trial

June 1, 2026

Entropy files new US patent for IBS program

May 4, 2026

TRP 8802 delivers 75% breakthrough response in IBS

May 3, 2026

TRP-8803 delivers repeatable, high-intensity effect

April 13, 2026

FY25 R&D Tax Incentive received

March 4, 2026

Cohort 1 enrolment achieved for TRP-8803 BED Trial

March 2, 2026

Appendix 4D and Half Year Report for period 31 Dec 2025

February 26, 2026

Australian Patent Secures TRP 8803 Platform to 2042

February 11, 2026

Quarterly Activities Report and Appendix 4C

January 29, 2026

First TRP-8803 BED patient shows broad clinical improvement

January 21, 2026

TRP-8802 Phase 2a Trial Shows Sustained BED Reduction

January 12, 2026

Decks in 2026